Form 4: NewAmsterdam Pharma Director Lange Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Director Louis G. Lange reports the acquisition and disposal of ordinary shares and restricted stock units in NewAmsterdam Pharma Co N.V. on March 26, 2025.
Summary
- On March 26, 2025, Director Louis G. Lange reported changes in beneficial ownership of NewAmsterdam Pharma Co N.V. securities.
- The transactions involved the acquisition of 3,102 ordinary shares and 3,308 restricted stock units (RSUs).
- Lange also disposed of 3,102 RSUs and 10,062 ordinary shares.
- The RSUs were granted on March 26, 2025, as earnout RSUs related to a prior business combination agreement.
- Some RSUs were fully vested upon grant, while others will vest in installments on April 1, 2025, May 1, 2025, and June 1, 2025, contingent on continued service.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing changes in beneficial ownership, with no inherent positive or negative sentiment.
Positives
- The granting of RSUs indicates that a clinical development milestone was achieved, as per the business combination agreement.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a director.
Key Dates
| Date | Description |
|---|---|
| 2022-07-25 | Date of the business combination agreement among NewAmsterdam Pharma, Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation. |
| 2025-03-26 | Date of the reported transactions: acquisition and disposal of ordinary shares and RSUs. |
| 2025-04-01 | Vesting date for 69 of the remaining RSUs. |
| 2025-05-01 | Vesting date for 69 of the remaining RSUs. |
| 2025-06-01 | Vesting date for 68 of the remaining RSUs. |
| 2025-03-28 | Date of signature for the Form 4 filing. |
Keywords
beneficial ownership, Form 4, NewAmsterdam Pharma, RSU, ordinary shares, director, Lange
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.